Despite the availability of multiple public health interventions, approximately 608,000 malaria deaths were recorded in 2022, with the majority of these deaths occurring in children under 5 years of age. Reducing the global malaria burden will require the development and implementation of new prevention strategies, including the use of vaccines, expanded monthly chemoprevention, and antibody-based prophylaxis. Multiple monoclonal antibodies (mAbs), including MAM01, that target conserved sequences within the circumsporozoite protein (CSP) for P. falciparum (Pf) infection prevention are in early development.
MAM01 is an engineered version of a human IgG1 (Immunoglobulin G1 subclass) mAb generated following vaccination with RTS,S/AS01 vaccine.
This age de-escalation and dose escalation study, aims to assess the safety and tolerability of intravenous (IV), subcutaneous (SC) and intramuscular (IM) injection of MAM01 in African adults (18-55years), young children (2-<5years, and 12months to <24months), and infants (3 to <12months) in a setting of prerrenial malaria transmission.
Expected impact: The results will help determine the future potential for mAbs as a new class of malaria prevention tools in moderate-high perennial transmission settings.
